

FULBRIGHT & JAWORSKI L.L.P.

A. REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER  
PARTNER

INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONG BEACH  
HONG KONG

RECEIVED  
JAN 23 2003  
FBI CENTER 1600/2900

January 14, 2003



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 14, 2003 Date	 Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/460,292 "COMPOSITIONS AND METHODS OF MODULATING  
"CHOLESTEROL METABOLISM" – David L. Mangelsdorf et al.  
F&J Matter Ref.: UTSD:596 / 10017652

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Amendment and Request for Reconsideration Under 37 C.F.R. §1.111; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

No other fees are believed due; however, should any other fees be due, applicants authorizes the Commissioner to debit Fulbright & Jaworski Deposit Acct. No. 55-1212/UTSD:596.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/fb

Encl.: As noted.